Skip to main content
Beijing Bohui Innovation Biotechnology Group Co., Ltd logo

Beijing Bohui Innovation Biotechnology Group Co., Ltd — Investor Relations & Filings

Ticker · 300318 ISIN · CNE000001QR4 LEI · 300300KKOT0G7W3YQ339 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,469 across all filing types
Latest filing 2026-04-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300318

About Beijing Bohui Innovation Biotechnology Group Co., Ltd

https://www.bohui-tech.com

Beijing Bohui Innovation Biotechnology Group Co., Ltd. is a high-tech enterprise specializing in the research, development, and manufacturing of advanced medical diagnostic systems and biopharmaceutical products. The company's core portfolio includes trace element analysis instruments, mass spectrometry systems, and molecular diagnostic reagents, with a significant focus on maternal and child health. Through its strategic acquisitions, the group has expanded into the biopharmaceutical sector, specifically the production of human blood products such as albumin and immunoglobulin. Bohui Innovation integrates diverse technological platforms, including atomic absorption spectroscopy and microfluidic chips, to provide comprehensive solutions for clinical testing and therapeutic monitoring. The company serves a broad range of medical institutions, blood centers, and research laboratories, emphasizing technological innovation and precision in healthcare diagnostics.

Recent filings

Filing Released Lang Actions
关于向银行等金融机构申请综合授信额度的公告
Capital/Financing Update Classification · 90% confidence The document is an official stock exchange announcement from Beijing Bohui Innovation Biotech Group (证券简称：博晖创新) describing the company’s board approval and forthcoming shareholder approval to apply for a comprehensive credit facility of up to RMB 2.9 billion from banks and financial institutions. This is a financing activity update regarding debt facilities. It is not a share issuance or dividend notice, nor an AGM material, but a financing arrangement. This matches the definition for Capital/Financing Update (CAP).
2026-04-24 Chinese
关于2026年度担保额度预计的公告
Regulatory Filings Classification · 78% confidence The document is an official corporate announcement (alias 公告) regarding the board’s approval of a proposed guarantee limit for various subsidiaries, to be submitted for shareholder approval. It contains typical disclosure under Shenzhen Stock Exchange rules, detailing amounts, counter-parties, procedures, and board resolutions. There is no indication it is an earnings release, annual or interim report, audit report, management change, dividend notice, or capital raise. It also is not merely a notice of report publication. This falls into the miscellaneous regulatory announcement category. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-24 Chinese
第八届董事会第十八次会议决议公告
Regulatory Filings Classification · 25% confidence The document is an announcement of the resolutions passed at the company’s 8th Board of Directors 18th meeting (e.g., approval of the annual work report, financial statements, audit report, profit distribution plan, share issuance plan, related‐party transactions, amendments to the articles, etc.). It is not the full annual report or audit report itself, nor an earnings release, nor a proxy statement. It is a general regulatory disclosure of board meeting resolutions required by the exchange. Accordingly, it falls into the fallback "Regulatory Filings" category (RNS).
2026-04-24 Chinese
2025年度财务决算报告
Interim / Quarterly Report Classification · 95% confidence The document is a '2025 Annual Financial Final Accounts Report' (2025年度财务决算报告) for Beijing Bohui Innovation Biotechnology Group Co., Ltd. It contains detailed financial statements, including balance sheets, income statements, cash flow statements, and comparative analysis of financial performance for the fiscal year 2025. While it references an audit report, it is not the audit report itself, nor is it a full 10-K annual report. It provides substantive financial data and management's analysis of the results, fitting the definition of an Interim/Quarterly Report (IR) in the context of comprehensive financial reporting for a specific period, even though it covers a full year (as it is a standalone financial summary report). FY 2025
2026-04-24 Chinese
关于营业收入扣除事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is issued by a CPA firm (大华会计师事务所) as a “专项核查意见” (special inspection opinion) on the company’s 2025 revenue deduction schedule. It includes the auditor’s responsibility and opinion sections, audit report number, references to Chinese auditing standards, and is a standalone audit document (not an announcement of an attached report). This matches the definition of a standalone Audit Report / Information (AR). FY 2025
2026-04-24 Chinese
董事会对独立董事独立性自查情况的专项报告
Governance Information Classification · 90% confidence The document is a special report by the board on the self-assessment of independent directors’ independence, referencing listing rules and the company’s governance charter. It is not an earnings release, director change notice, or call transcript but rather a governance compliance report about board structure and independent director rules. This aligns with the Governance Information category.
2026-04-24 Chinese

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.